Viagra patent?

Viagra (sildenafil citrate)
Viagra is a brand name drug that was first introduced by Pfizer in 1998. It was the first oral medication approved for the treatment of erectile dysfunction (ED) and quickly became a blockbuster product. The patent landscape for Viagra is an interesting case study of how pharmaceutical patents work, how they are enforced, and how generics eventually entered the market.

1. The Original Patent

• Original Inventors: Pfizer scientists in collaboration with the University of Dundee and the University of the West of England (UK) and the University of Washington (US).
• Key Patent Claims: The patents covered not only the chemical synthesis of sildenafil citrate but also its therapeutic use in treating ED.
• Patent Expiration: All of the main patents expired between 2002 and 2005, depending on the jurisdiction.

2. Generic Entry

• First Generic: In 2014, Mylan (now part of Viatris) and Teva launched a generic sildenafil formulation in the U.S. under the brand name “Revatio” (originally intended for pulmonary arterial hypertension).
• Market Impact: Generic availability dramatically lowered the price of sildenafil from several hundred dollars per month to less than a dollar per pill in many markets.

3. Patent Extensions and Legal Actions

While the core patents expired in the mid‑2000s, Pfizer pursued several legal tactics to delay generic competition:

1. Patent Term Extensions (PTE):

   • The FDA can grant up to 5 years of extension to compensate for the time spent in clinical trials and regulatory review.
   • Pfizer obtained PTEs that pushed the commercial launch of generics later than the original expiration dates.

2. Secondary Patents (Secondary Claims):

   • Pfizer filed patents on formulations, dosage forms (e.g., “rapid‑release” tablets), and specific combinations (e.g., sildenafil with other active ingredients).
   • These secondary patents were often contested in court, with mixed results.

3. Litigation:

   • Pfizer engaged in several lawsuits against generic manufacturers, claiming infringement on secondary patents.
   • Courts ultimately ruled that many of those secondary claims were not sufficiently novel or were invalid, leading to the rapid entry of generics.

4. Current Status (as of 2026)

5. How Patents Work for Drugs (Quick Primer)

1. Innovation: A company discovers a new molecule or a new use for an existing molecule.
2. Patent Filing: The company files a patent application that must be novel, non‑obvious, and useful.
3. Patent Grant: After examination, the patent office grants a patent, usually for 20 years from filing.
4. Regulatory Approval: Separately, the company submits a New Drug Application (NDA) to regulatory bodies (FDA, EMA, etc.).
5. Patent Term Extensions: The FDA can grant up to 5 years of additional marketing exclusivity to cover clinical trials and approval delays.
6. Generics: Once the patent expires (or a generic manufacturer overcomes it through litigation), other manufacturers can produce “bioequivalent” versions.

6. Bottom Line

• Viagra’s original patents expired between 2002‑2005, allowing generic competitors to enter the market.
• Pfizer used secondary patents and legal maneuvers to delay generics, but most were overturned.
• Today the drug is widely available in generic form, and the brand remains strong but no longer dominant in terms of pricing.

Quick FAQ

If you want more specific details—like the status in a particular country, or how a particular generic manufacturer has challenged the patents—just let me know!